Minerva Neurosciences (NERV) Stock: Buy, Sell, or Hold?
NERV - Minerva Neurosciences, Inc
$4.15
-0.01 (-0.24%)
▼
5d:
-11.51%
30d:
+5.87%
90d:
-10.17%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When NERV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NERV is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NERV is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NERV is currently trading at $4.15, which is considered oversold relative to its 30-day fair value range of $4.19 to $4.88.
Technical Outlook: Technically, NERV is in a downtrend. The price is currently testing key support at $4.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NERV scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.33 (+149.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NERV is in a downtrend. The price is currently testing key support at $4.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NERV scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.33 (+149.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.19 -
$4.88
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.0% below Wall St target ($10.33)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.19 -
$4.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.10
Resistance Level
$5.30
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.88
Wall Street Target
$10.33
(+149.0%)
Share & Embed Analysis
Last updated: September 13, 2026 6:55 PM ET
Data refreshes hourly during market hours. Next update: 7:55 PM
Data refreshes hourly during market hours. Next update: 7:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NERV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$106 | 41 HOLD |
